A recent report on a phase Ib/II clinical trial of HVP-specific DNA vaccine of 21 HNSCC patients also demonstrated an overall ~85% of the patients showed an increase in IFN-γ producing antigen-specific T cells that lasted longer than 1-year (Aggarwal et al., 2018). The gene discussed is IFNG; the disease is head and neck squamous cell carcinoma.